Chimeric Therapeutics Ltd. (AU:CHM) has released an update.
Chimeric Therapeutics announced the progression of its Phase 1B ADVENT-AML clinical trial to a new cohort, testing a higher dose of its NK cell therapy CHM CORE-NK in combination with the standard care for acute myeloid leukemia. The first cohort, which included three patients with relapsed or refractory AML, showed no dose-limiting toxicities, allowing the trial to move forward. Chimeric is an Australian biotech firm focused on developing innovative cancer cell therapies, with several clinical programs ongoing and more planned for 2024.
For further insights into AU:CHM stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
